Why Did INKT Stock Skyrocket in Today’s Premarket Trading?

MiNK Therapeutics (NASDAQ: INKT) shares are experiencing a massive surge in premarket trading, jumping over 213% to $24.20 as of 8:01 AM EDT on July 11, 2025. The dramatic price movement comes after the company announced groundbreaking results from its cancer treatment trials, including a complete remission case published in the prestigious journal Nature’s Oncogene. This represents a significant milestone for the clinical-stage biotech company, which has been developing innovative immune cell therapies to treat hard-to-cure cancers.

MiNK’s Breakthrough in Cancer Treatment

The company’s experimental treatment, called agenT-797, achieved something remarkable: it completely eliminated cancer in a patient who had already failed multiple standard treatments.
This patient had testicular cancer that had spread throughout the body and didn’t respond to chemotherapy, stem cell transplants, or several different immunotherapy drugs. After receiving a single infusion of agenT-797 combined with an existing cancer drug, the patient showed no signs of cancer for over two years.

What makes this particularly impressive is that agenT-797 is an “off-the-shelf” treatment, meaning it doesn’t need to be customized for each patient like some other cell therapies. The treatment uses special immune cells called invariant natural killer T (iNKT) cells that act like both soldiers and generals in the immune system – they can directly kill cancer cells while also coordinating other immune responses. The therapy was well-tolerated with no serious side effects, which is crucial for bringing any new treatment to market.

This breakthrough has significant implications for both MiNK and the broader cancer treatment industry. For MiNK, it validates their core technology platform and could accelerate development of their pipeline. For the industry, it demonstrates that allogeneic (donor-derived) cell therapies can work effectively against solid tumors, which has been a major challenge in cancer immunotherapy.
The company also reported encouraging results in gastric cancer patients, with some achieving extended survival beyond 12 months in a setting where such outcomes are rare.

INKT Stock Skyrockets in Premarket Trading

As of 8:01 AM EDT on July 11, 2025, INKT stock was trading at $24.20 in premarket, representing a staggering 213.07% increase from the previous day’s close of $7.73. The stock had already gained 6.16% in regular trading the day before, closing up $0.45. This dramatic premarket surge brings the company’s market capitalization to approximately $95 million, up from around $31 million at the previous close.

The company’s financial profile reflects its clinical-stage status, with no current revenue and recent quarterly losses of $9.74 million. MiNK maintains $3.23 million in cash, which will be crucial for funding ongoing clinical trials. The stock has been volatile over the past year, with a 52-week range of $4.56 to $13.79, making today’s premarket price significantly above the previous high.

Despite the strong premarket performance, investors should note that MiNK remains a speculative biotech investment with typical clinical-stage risks.
The company’s success depends on advancing its trials, securing regulatory approvals, and eventually commercializing its treatments. However, today’s breakthrough data significantly strengthens the investment thesis by demonstrating proof-of-concept for their core technology platform in treating some of the most challenging cancers.

—

Originally Posted on July 11, 2025 – Why Did INKT Stock Skyrocket in Today’s Premarket Trading?

Disclosure: Tim Fries has no positions in any of the stocks mentioned, and has no plans to initiate any positions within the 72 hours following the publishing of this article. This article expresses the opinions of Tim Fries. Tokenist Media LLC has no position in any of the stocks mentioned, and does not plan to initiate any positions within 72 hours of the publishing of this article. Please consult our website policy for more information.